<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39360822</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine.</ArticleTitle><Pagination><StartPage>2412623</StartPage><MedlinePgn>2412623</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2412623</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2024.2412623</ELocationID><Abstract><AbstractText>SARS-CoV-2 ancestral strain-induced immune imprinting poses great challenges to updating vaccines for new variants. Studies showed that repeated Omicron exposures could override immune imprinting induced by inactivated vaccines but not mRNA vaccines, a disparity yet to be understood. Here, we analyzed the immune imprinting alleviation in inactivated vaccine (CoronaVac) cohorts after a long-term period following breakthrough infections (BTI). We observed in CoronaVac-vaccinated individuals who experienced BA.5/BF.7 BTI, the proportion of Omicron-specific memory B cells (MBCs) substantially increased after an extended period post-Omicron BTI, with their antibodies displaying enhanced somatic hypermutation and neutralizing potency. Consequently, the neutralizing antibody epitope distribution encoded by MBCs post-BA.5/BF.7 BTI after prolonged maturation closely mirrors that in BA.5/BF.7-infected unvaccinated individuals. Together, these results indicate the activation and expansion of Omicron-specific naïve B cells generated by first-time Omicron exposure helped to alleviate CoronaVac-induced immune imprinting, and the absence of this process should have caused the persistent immune imprinting seen in mRNA vaccine recipients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yisimayi</LastName><ForeName>Ayijiang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Weiliang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jian</LastName><ForeName>Fanchong</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Yuanling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaosu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute for Immunology, College of Life Sciences, Nankai University, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yanli</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Ran</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Haiyan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Ronghua</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Zhongyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Organ Transplant Center, NHC Key Laboratory for Critical Care Medicine, Tianjin First Central Hospital, Nankai University, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Youchun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9769-5141</Identifier><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Biotechnology, Chinese Academy of Medical Science &amp; Peking Union Medical College, Kunming, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Yunlong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biomedical Pioneering Innovation Center (BIOPIC), School of Life Sciences, College of Chemistry and Molecular Engineering, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Changping Laboratory, Beijing, People's Republic of China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000706269">SARS-CoV-2 inactivated vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName><SupplMeshName Type="Disease" UI="C000718127">COVID-19 breakthrough infections</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000091245" MajorTopicYN="N">Memory B Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093742" MajorTopicYN="N">Breakthrough Infections</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Omicron breakthrough infection</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 RBD</Keyword><Keyword MajorTopicYN="N">antibody responses</Keyword><Keyword MajorTopicYN="N">epitope distribution</Keyword><Keyword MajorTopicYN="N">immune imprinting</Keyword></KeywordList><CoiStatement>Yunlong Cao is inventor on the provisional patent applications of BD series antibodies, which include BD55-5514 (SA55) and monoclonal antibodies from Omicron infection convalescents. Yunlong Cao is founder of Singlomics Biopharmaceuticals. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39360822</ArticleId><ArticleId IdType="pmc">PMC11486138</ArticleId><ArticleId IdType="doi">10.1080/22221751.2024.2412623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Francis T. On the doctrine of original antigenic Sin. Proc Am Philos Soc. 1960;104(6):572–578.</Citation></Reference><Reference><Citation>Lessler J, Riley S, Read JM, et al. . Evidence for antigenic seniority in influenza A (H3N2) antibody responses in Southern China. PLoS Pathog. 2012;8(7):e1002802. doi:10.1371/journal.ppat.1002802</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002802</ArticleId><ArticleId IdType="pmc">PMC3400560</ArticleId><ArticleId IdType="pubmed">22829765</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Jian F, Wang J, et al. . Imprinted SARS-CoV-2 humoral immunity induces convergent omicron RBD evolution. Nature. 2023 Feb;614(7948):521–529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsoussi WB, Malladi SK, Zhou JQ, et al. . SARS-CoV-2 omicron boosting induces de novo B cell response in humans. Nature. 2023 May;617(7961):592–598. doi:10.1038/s41586-023-06025-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06025-4</ArticleId><ArticleId IdType="pubmed">37011668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku CI, Bergeron AJ, Ahlm C, et al. . Recall of preexisting cross-reactive B cell memory after omicron BA.1 breakthrough infection. Sci Immunol. 2022 Jul 29;7(73):eabq3511. doi:10.1126/sciimmunol.abq3511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq3511</ArticleId><ArticleId IdType="pmc">PMC9097882</ArticleId><ArticleId IdType="pubmed">35549299</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YJ, Pinto D, Walls AC, et al. . Imprinted antibody responses against SARS-CoV-2 omicron sublineages. Science. 2022 Nov 11;378(6620):619–627. doi:10.1126/science.adc9127</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adc9127</ArticleId><ArticleId IdType="pubmed">36264829</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt J, Muik A, Salisch N, et al. . Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci Immunol. 2022 Sep 16;7(75):eabq2427. doi:10.1126/sciimmunol.abq2427</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq2427</ArticleId><ArticleId IdType="pmc">PMC9162083</ArticleId><ArticleId IdType="pubmed">35653438</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Yisimayi A, Jian F, et al. . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection. Nature. 2022 Aug;608(7923):593–602. doi:10.1038/s41586-022-04980-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku CI, Starr TN, Zhou P, et al. . Evolution of antibody immunity following omicron BA.1 breakthrough infection. Nat Commun. 2023 May 12;14(1):2751. doi:10.1038/s41467-023-38345-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38345-4</ArticleId><ArticleId IdType="pmc">PMC10180619</ArticleId><ArticleId IdType="pubmed">37173311</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A, Piccoli L, Case JB, et al. . Neutralization, effector function and immune imprinting of omicron variants. Nature. 2023 Sep;621(7979):592–601. doi:10.1038/s41586-023-06487-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06487-6</ArticleId><ArticleId IdType="pmc">PMC10511321</ArticleId><ArticleId IdType="pubmed">37648855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici MA, Addetia A, Seo AJ, et al. . Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity. 2024 Apr 9;57(4):904–911 e4. doi:10.1016/j.immuni.2024.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2024.02.016</ArticleId><ArticleId IdType="pubmed">38490197</ArticleId></ArticleIdList></Reference><Reference><Citation>Yisimayi A, Song W, Wang J, et al. . Repeated omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 2024 Jan;625(7993):148–156. doi:10.1038/s41586-023-06753-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06753-7</ArticleId><ArticleId IdType="pmc">PMC10764275</ArticleId><ArticleId IdType="pubmed">37993710</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, et al. . Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022 Feb;602(7898):657–663. doi:10.1038/s41586-021-04385-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim WW, Mak L, Leung GM, et al. . Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe. 2021 Sep;2(9):e423. doi:10.1016/S2666-5247(21)00177-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00177-4</ArticleId><ArticleId IdType="pmc">PMC8282488</ArticleId><ArticleId IdType="pubmed">34308395</ArticleId></ArticleIdList></Reference><Reference><Citation>Tas JM, Koo J-H, Lin Y-C, et al. . Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses. Immunity. 2022;55(10):1856–1871.e6. doi:10.1016/j.immuni.2022.07.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.07.020</ArticleId><ArticleId IdType="pmc">PMC9350677</ArticleId><ArticleId IdType="pubmed">35987201</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer-Babajew D, Wang Z, Muecksch F, et al. . Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature. 2023;613(7945):735–742. doi:10.1038/s41586-022-05609-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05609-w</ArticleId><ArticleId IdType="pmc">PMC9876794</ArticleId><ArticleId IdType="pubmed">36473496</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiepers A, van’t Wout MF, Greaney AJ, et al. . Molecular fate-mapping of serum antibody responses to repeat immunization. Nature. 2023;615(7952):482–489. doi:10.1038/s41586-023-05715-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-05715-3</ArticleId><ArticleId IdType="pmc">PMC10023323</ArticleId><ArticleId IdType="pubmed">36646114</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie J, Li Q, Wu J, et al. . Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc. 2020 Nov;15(11):3699–3715. doi:10.1038/s41596-020-0394-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-020-0394-5</ArticleId><ArticleId IdType="pubmed">32978602</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>